首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin DEC205 and Clec9A
【2h】

Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin DEC205 and Clec9A

机译:通过将HIV gag p24靶向LangerinDEC205和Clec9A抗体中的CD8树突状细胞可比较T辅助细胞1(Th1)和CD8 T细胞免疫

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Improved protein-based vaccines should facilitate the goal of effective vaccines against HIV and other pathogens. With respect to T cells, the efficiency of immunization, or “immunogenicity,” is improved by targeting vaccine proteins to maturing dendritic cells (DCs) within mAbs to DC receptors. Here, we compared the capacity of Langerin/CD207, DEC205/CD205, and Clec9A receptors, each expressed on the CD8+ DC subset in mice, to bring about immunization of microbial-specific T cells from the polyclonal repertoire, using HIV gag-p24 protein as an antigen. α-Langerin mAb targeted splenic CD8+ DCs selectively in vivo, whereas α-DEC205 and α-Clec9A mAbs targeted additional cell types. When the mAb heavy chains were engineered to express gag-p24, the α-Langerin, α-DEC205, and α-Clec9A fusion mAbs given along with a maturation stimulus induced comparable levels of gag-specific T helper 1 (Th1) and CD8+ T cells in BALB/c × C57BL/6 F1 mice. These immune T cells were more numerous than targeting the CD8 DC subset with α-DCIR2-gag-p24. In an in vivo assay in which gag-primed T cells were used to report the early stages of T-cell responses, α-Langerin, α-DEC205, and α-Clec9A also mediated cross-presentation to primed CD8+ T cells if, in parallel to antigen uptake, the DCs were stimulated with α-CD40. α-Langerin, α-DEC205, and α-Clec9A targeting greatly enhanced T-cell immunization relative to nonbinding control mAb or nontargeted HIV gag-p24 protein. Therefore, when the appropriate subset of DCs is targeted with a vaccine protein, several different receptors expressed by that subset are able to initiate combined Th1 and CD8+ immunity.
机译:改进的基于蛋白质的疫苗应有助于实现针对艾滋病毒和其他病原体的有效疫苗的目标。对于T细胞,通过将疫苗蛋白靶向mAb内成熟的树突状细胞(DC)至DC受体,可以提高免疫效率或“免疫原性”。在这里,我们比较了分别在小鼠的CD8 + DC亚群上表达的Langerin / CD207,DEC205 / CD205和Clec9A受体从多克隆抗体中免疫微生物特异性T细胞的能力。使用HIV gag-p24蛋白作为抗原。 α-LangerinmAb在体内选择性靶向脾脏CD8 + DC,而α-DEC205和α-Clec9AmAb则靶向其他细胞类型。当将mAb重链改造为表达gag-p24时,与成熟刺激一起使用的α-Langerin,α-DEC205和α-Clec9A融合mAb可以诱导相当水平的gag特异性T辅助因子1(Th1)和CD8 < BALB / c×C57BL / 6 F1小鼠的sup> + T细胞。这些免疫T细胞比用α-DCIR2-gag-p24靶向CD8 - DC子集的数量更多。在体内实验中,使用gag引发的T细胞报告了T细胞应答的早期阶段,α-Langerin,α-DEC205和α-Clec9A也介导了与引发的CD8 + <如果与抗原摄取平行,则用α-CD40刺激DC。相对于非结合对照mAb或非靶向HIV gag-p24蛋白,靶向α-Langerin,α-DEC205和α-Clec9A的T细胞免疫大大增强。因此,当以疫苗蛋白靶向DC的适当子集时,该子集表达的几种不同受体能够启动Th1和CD8 + 联合免疫。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号